Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Phase 3 trial data point to more options for patients with relapsed or refractory multiple myeloma: Teclistamab- and mezigdomide-based regimens could expand treatment options, set new standards of care, and improve survival.

Created on 14 Nov 2026

Authors

Leah Lawrence

Published in

Cancer. Volume 132. Issue 22. Nov 15, 2026.

PMID:
43031548
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement